2008调脂治疗进展与回顾精选.pptVIP

主要内容 新型调脂药胆固醇吸收抑制剂----ENHANCE、SEAS TRIAL带给我们的思考 他汀能否改善慢性心力衰竭患者预后? 他汀多途径抗动脉粥样硬化—干预炎症反应 评估AS 风险的指标:替代终点 or/and 临床终点? LDL-C----抗AS首要干预目标 依托循证，重返他汀时代 ENHANCE TRIALSimvastatin With or Without Ezetimibe in Familial Hypercholesterolemia BACKGROUND Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of LDL-c when added to statin treatment. However, the effect of Ezetimibe on the progression of atherosclerosis is unknown SEAS TRIAL Simvastatin Ezetimibe in Aortic Stenosis BACKGROUND: Previous studies assessing the impact of statin therapy on aortic valve stenosis (AoVS) have demonstrated mixed results. PURPOSE: To determine the effects of long term intensive cholesterol lowing on AoVS. DESIGN: Randomized, double blind study of 1,873 patients with mild moderate, asympomatic aortic stenosis randomized to: 40mg simvastatin plus 10mg of ezetimibe(n=944) or placebo(n=929). Median follow up=52.2 months. SEAS TRIAL Simvastatin Ezetimibe in Aortic Stenosis Primary Endpoint: Composite of CV events: CV death; AoV replacement, nonfatal MI, hospitalization for HF,USA,CABG,PCI non-hemorrhagic stroke. Secondary Endpoint: Events related to AoVS ischemic CV events SEAS TRIAL Simvastatin Ezetimibe in Aortic Stenosis SEAS TRIAL Simvastatin Ezetimibe in Aortic Stenosis Conclusion: Smivastatin/Ezetimibe therapy do not reduce combined AoV events ischemic events in pts with AoVS; therapy did reduce the incidence of ischemic CV events. Implications: Lipid lowing therapy can be used to reduce the risk of ischemic CV events. Cancer incidence needs to be further analyzed. 主要内容 新型调脂药胆固醇吸收抑制剂----ENHANCE、SEAS 带给我们的思考 他汀能否改善慢性心力衰竭患者预后? 他汀多途径抗动脉粥样硬化—干预炎症反应 评估AS 风险的指标:替代终点 or/and 临床终点? LDL-C----抗AS首要干预目标 依托循证，重返他汀时代 The GISSI-HF TRIALEffects of rosuvastatin in patients with symptomatic chronic HF BACKGROUND: Pleiotropic actions of statins may target components of the complex syndrome of HF. While observational studies, small RCTs etc, suggest a decrease in CV mortality in HF pat